PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; August 8, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - PepGen Inc. is facing a class action lawsuit due to alleged misleading statements regarding its lead product candidate, PGN-EDO51, and the safety and efficacy of its clinical trials, which has resulted in significant stock price declines during the class period [3][4][5][6][7]. Group 1: Company Overview - PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with PGN-EDO51 targeting Duchenne muscular dystrophy (DMD) as its lead product candidate [3]. Group 2: Allegations and Stock Performance - The class action lawsuit claims that PepGen made false or misleading statements about PGN-EDO51's safety and effectiveness, the adequacy of the CONNECT2 clinical trial, and the company's clinical and regulatory prospects [3]. - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but the results were deemed disappointing by analysts, leading to a nearly 33% decline in stock price [4]. - On December 16, 2024, PepGen received a clinical hold notice from the FDA regarding the CONNECT2 study, causing further stock decline [5]. - On January 29, 2025, dosing in the CONNECT1 study was paused due to safety concerns, resulting in a stock decline of approximately 22% [6]. - On March 4, 2025, PepGen announced a voluntary temporary pause of the CONNECT2 study, leading to another stock drop of nearly 19% [7].